资料显示，上海澳华内镜股份有限公司位于上海市闵行区光中路133弄66号，成立日期1994年10月27 日，上市日期2021年11月15日，公司主营业务涉及从事电子内窥镜设备及内窥镜诊疗手术耗材研发、生 产和销售的高新技术企业。主营业务收入构成为：内窥镜设备92.35%，内窥镜诊疗耗材3.71%，内窥镜 维修服务收入3.58%，租赁收入0.35%。 天弘臻选健康混合A（014708）基金经理为刘盟盟。 截至发稿，刘盟盟累计任职时间8年18天，现任基金资产总规模13.85亿元，任职期间最佳基金回报 57.37%， 任职期间最差基金回报-10.8%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 从基金十大重仓股角度 数据显示，天弘基金旗下1只基金重仓澳华内镜。天弘臻选健康混合A（014708）四季度减持2.01万股， 持有股数4.84万股，占基金净值比例为7.82%，位居第六大重仓股。根据测算，今日浮亏损失约11.28万 元。 天弘臻 ...

截至9月30日，澳华内镜股东户数5549.00，较上期增加41.52%；人均流通股24268股，较上期减少 29.34%。2025年1月-9月，澳华内镜实现营业收入4.23亿元，同比减少15.57%；归母净利润-5609.25万 元，同比减少250.37%。 分红方面，澳华内镜A股上市后累计派现7628.41万元。近三年，累计派现5094.95万元。 机构持仓方面，截止2025年9月30日，澳华内镜十大流通股东中，富国精准医疗灵活配置混合A （005176）位居第三大流通股东，持股534.06万股，相比上期增加50.55万股。汇添富创新医药混合A （006113）位居第五大流通股东，持股358.52万股，相比上期减少31.33万股。汇添富医疗服务灵活配置 混合A（001417）位居第八大流通股东，持股204.51万股，相比上期减少24.36万股。工银前沿医疗股票 A（001717）、广发医疗保健股票A（004851）退出十大流通股东之列。 责任编辑：小浪快报 1月22日，澳华内镜跌1.57%，成交额4586.25万元。两融数据显示，当日澳华内镜获融资买入额440.37 万元，融资偿还320.75万元，融资净买 ...

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has experienced a decline in both revenue and net profit, indicating potential challenges in its financial performance [2] - As of December 24, Aohua Endoscopy's stock price decreased by 0.04%, with a trading volume of 58.05 million yuan and a net financing buy of -2.62 million yuan [1] - The company's financing balance reached 125 million yuan, accounting for 2.07% of its market capitalization, which is above the 80th percentile of the past year [1] Group 2 - For the period from January to September 2025, Aohua Endoscopy reported a revenue of 423 million yuan, a year-on-year decrease of 15.57%, and a net profit attributable to shareholders of -56.09 million yuan, a significant decline of 250.37% [2] - The number of shareholders increased by 41.52% to 5,549, while the average circulating shares per person decreased by 29.34% to 24,268 shares [2] - Aohua Endoscopy has distributed a total of 76.28 million yuan in dividends since its A-share listing, with 50.95 million yuan distributed in the last three years [3]

Core Viewpoint - Aohua Endoscopy experienced a decline of 3.21% in stock price on December 23, with a trading volume of 69.16 million yuan, indicating potential investor concerns regarding the company's financial performance and market position [1]. Financing and Trading Data - On December 23, Aohua Endoscopy had a financing buy-in amount of 8.64 million yuan, with a net financing buy of 5.35 million yuan after repayments [1]. - The total financing and securities balance reached 128 million yuan, accounting for 2.11% of the circulating market value, which is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - The company had no short selling activity on December 23, with a short selling balance of 28.72 thousand yuan, also above the 90th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Aohua Endoscopy reported a revenue of 423 million yuan, a year-on-year decrease of 15.57%, and a net profit attributable to shareholders of -56.09 million yuan, reflecting a significant decline of 250.37% [2]. - Cumulative cash dividends since the company's A-share listing amount to 76.28 million yuan, with 50.95 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 41.52% to 5,549, while the average circulating shares per person decreased by 29.34% to 24,268 shares [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by the third-largest shareholder, with a 50.55 thousand share increase, while other funds reduced their holdings [3].

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a significant increase in its stock price, rising by 5.42% to 49.39 CNY per share, with a total market capitalization of 6.651 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The company's main revenue sources are: endoscopy equipment (92.35%), endoscopy diagnostic consumables (3.71%), endoscopy maintenance services (3.58%), and leasing income (0.35%) [1] Group 2 - According to data, Aohua Endoscopy is a top ten holding in the Agricultural Bank of China Fund's Aohua Specialized and New Mixed Fund (016305), which increased its holdings by 2,831 shares in the third quarter, now holding 57,300 shares, representing 2.32% of the fund's net value [2] - The Aohua Specialized and New Mixed Fund has achieved a year-to-date return of 47.01%, ranking 1,341 out of 8,148 in its category, and a one-year return of 37.65%, ranking 1,639 out of 8,053 [2] - The fund manager, Wei Gang, has been in position for 7 years and 229 days, with the fund's total asset size at 540 million CNY and a best return of 131.83% during his tenure [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a stock price increase of 5.1%, reaching 51.73 yuan per share, with a total market capitalization of 6.966 billion yuan [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] - The company is classified as a high-tech enterprise, with additional revenue sources including endoscope consumables (3.71%), maintenance services (3.58%), and leasing (0.35%) [1] Group 2 - Xiangcai Fund has a significant holding in Aohua Endoscopy, with its Xiangcai Medical Health Mixed A fund holding 18,000 shares, representing 4.8% of the fund's net value [2] - The fund has achieved a year-to-date return of 44.3%, ranking 1642 out of 8155 in its category, and a one-year return of 36.51%, ranking 2016 out of 8029 [2] - The fund manager, Zhang Quan, has been in position for 1 year and 308 days, with the fund's total assets amounting to 18.3775 million yuan [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a stock price increase of 5.3%, reaching 50.86 CNY per share, with a total market capitalization of 6.849 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] - The company is located in Minhang District, Shanghai, and was listed on November 15, 2021 [1] Group 2 - Among the top ten circulating shareholders of Aohua Endoscopy, one fund from GF Fund Management, the GF Healthcare Stock A (004851), has entered the list, holding 1.7267 million shares, which is 1.28% of the circulating shares [2] - The GF Healthcare Stock A fund was established on August 10, 2017, and has a current scale of 5.247 billion CNY, with a year-to-date return of 19.8% [2] - The fund's performance ranks 2665 out of 4218 in its category this year, and it has achieved a cumulative return of 93.64% since inception [2] Group 3 - The fund manager of GF Healthcare Stock A is Wu Xingwu, who has been in the position for 10 years and 258 days, managing assets totaling 9.853 billion CNY [3] - During his tenure, the best fund return achieved was 105.25%, while the worst return was -37.23% [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a significant increase in its stock price, rising by 5.45% to 49.88 CNY per share, with a total market capitalization of 6.717 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The company's main revenue sources are: endoscopy equipment (92.35%), endoscopy consumables (3.71%), endoscopy maintenance services (3.58%), and leasing income (0.35%) [1] Group 2 - Aohua Endoscopy is a significant holding in the fund managed by Agricultural Bank of China, with the Aohua Endoscopy stock representing 2.58% of the fund's net value, making it the fifth-largest holding [2] - The Agricultural Bank of China fund, named Agricultural Bank of China Specialized and New Mixed A (016305), has achieved a year-to-date return of 39.95% and ranks 1392 out of 8162 in its category [2] - The fund manager, Wei Gang, has been in charge for over 7 years, with the best fund return during his tenure being 121.47% [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy experienced a stock price increase of 5.45%, reaching 49.88 CNY per share, with a total market capitalization of 6.717 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The revenue composition of Aohua Endoscopy includes 92.35% from endoscopy equipment, 3.71% from endoscopic diagnostic consumables, 3.58% from maintenance services, and 0.35% from leasing [1] Group 2 - Among the top ten circulating shareholders of Aohua Endoscopy, ICBC Credit Suisse Fund's Aohua Medical Stock A (001717) reduced its holdings by 805,800 shares, now holding 3.0942 million shares, which is 2.3% of the circulating shares [2] - The Aohua Medical Stock A fund has achieved a year-to-date return of 26.76% and a one-year return of 20.01%, ranking 1686 out of 4218 and 2253 out of 3868 in its category, respectively [2] - The fund manager, Zhao Bei, has been in position for 10 years and 341 days, with the fund's total asset size at 16.425 billion CNY and a best return of 233% during his tenure [3]

Group 1 - The stock price of Aohua Endoscopy has declined by 1.57% to 46.25 CNY per share, with a total market capitalization of 6.228 billion CNY, and a cumulative drop of 9.46% over the last four days [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] Group 2 - Beixin Ruifeng Fund holds 100,000 shares of Aohua Endoscopy in its health lifestyle theme flexible allocation fund, representing 5.48% of the fund's net value, with a floating loss of approximately 74,000 CNY today and 483,000 CNY over the four-day decline [2] - The Beixin Ruifeng Health Lifestyle Theme Flexible Allocation Fund (001056) has a total scale of 90.1431 million CNY and has achieved a year-to-date return of 29.83% [2]